<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03250377</url>
  </required_header>
  <id_info>
    <org_study_id>EP0085</org_study_id>
    <nct_id>NCT03250377</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Japanese Subjects &gt;=16 Years of Age With Partial Seizures With or Without Secondary Generalization</brief_title>
  <official_title>An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Japanese Subjects &gt;=16 Years of Age With Partial Seizures With or Without Secondary Generalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the long-term safety and tolerability of BRV in focal
      epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV
      over time.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 5, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events (AEs) during the study</measure>
    <time_frame>From study entry until Final Visit (up to 70 months)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects who withdraw from the study due to Adverse Events (AEs)</measure>
    <time_frame>From study entry until Final Visit (up to 70 months)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Serious Adverse Events (SAEs) during the study</measure>
    <time_frame>From study entry until Final Visit (up to 70 months)</time_frame>
    <description>A SAE must meet 1 or more of the following criteria:
Death
Life-threatening
Significant or persistent disability/incapacity
Congenital anomaly/birth defect
Initial inpatient hospitalization or prolongation of hospitalization
Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in partial seizure frequency per 28 days from Baseline of EP0083 or N01358 by 3-month periods over the Evaluation Period</measure>
    <time_frame>Baseline of EP0083 or N01358 and by 3-month periods over the Evaluation Period (up to 70 months)</time_frame>
    <description>The seizure frequency is calculated as number of seizures per 28 days. This evaluation will be done every 3 months over the Evaluation Period.
Percent change in seizure frequency from Baseline of EP0083 (NCT03083665) or N01358 (NCT01261325) is calculated from the seizure frequency during the 3-month period and that at Baseline of EP0083 or N01358.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate in partial seizure frequency per 28 days by 3-month periods over the Evaluation Period</measure>
    <time_frame>Baseline of EP0083 or N01358 and by 3-month periods over the Evaluation Period (up to 70 months)</time_frame>
    <description>The seizure frequency is calculated as number of seizures per 28 days. This evaluation will be done every 3 months over the Evaluation Period.
A responder is defined as a subject with a &gt;= 50% reduction in seizure frequency from the Baseline Period of EP0083 or N01358.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects continuously seizure-free for partial seizure and all seizure types (partial, generalized, and unclassified epileptic seizure) for at least 6 months during the Evaluation Period</measure>
    <time_frame>During the Evaluation Period (up to 70 months)</time_frame>
    <description>A subject was considered seizure free, if no seizure occurred during 6 consecutive months in the Evaluation Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects continuously seizure-free for partial seizure and all seizure types (partial, generalized, and unclassified epileptic seizure) for at least 12 months during the Evaluation Period</measure>
    <time_frame>During the Evaluation Period (up to 70 months)</time_frame>
    <description>A subject was considered seizure free, if no seizure occurred during 12 consecutive months in the Evaluation Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal findings in laboratory tests</measure>
    <time_frame>By 3-month periods over the Evaluation Period (up to 70 months)</time_frame>
    <description>Safety will be assessed by number of subjects with abnormal findings in laboratory tests (blood chemistry, hematology, and urinalysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal findings in vital signs</measure>
    <time_frame>By 3-month periods over the Evaluation Period (up to 70 months)</time_frame>
    <description>Safety will be assessed by number of subjects with abnormal findings in vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal findings in body weight</measure>
    <time_frame>By 3-month periods over the Evaluation Period (up to 70 months)</time_frame>
    <description>Safety will be assessed by number of subjects with abnormal findings in body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal findings in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>By 3-month periods over the Evaluation Period (up to 70 months)</time_frame>
    <description>Safety will be assessed by number of subjects with abnormal findings in 12-lead electrocardiogram (ECG)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Partial Seizures With or Without Secondary Generalization</condition>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Brivaracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive open-label Brivaracetam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Pharmaceutical form: Film-coated tablet
Concentration: 25 mg and 50 mg
Route of administration: Oral use</description>
    <arm_group_label>Brivaracetam</arm_group_label>
    <other_name>Briviact</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/female subject from 16 years of age or older. Subjects who are not legal adults
             may only be included where legally permitted and ethically accepted.

          -  Subject completed the Treatment Period and Transition Period of EP0083 or is ongoing
             in N01379 sites in Japan.

          -  Female subjects with childbearing potential are eligible if they use a medically
             accepted contraceptive method.

        Exclusion Criteria:

          -  Subject has developed hypersensitivity to any components of the investigational
             medicinal product (IMP) or comparative drugs as stated in this protocol during the
             course of the core study.

          -  Severe medical, neurological or psychiatric disorders, or laboratory values which may
             have an impact on the safety of the subject.

          -  Poor compliance with the visit schedule or medication intake in the previous BRV
             studies.

          -  Planned participation in any other clinical study of another investigational drug or
             device during this study.

          -  Pregnant or lactating woman.

          -  Any medical condition which, in the Investigator's opinion, warrants exclusion.

          -  Subject has a lifetime history of suicide attempt or has suicidal ideation in the past
             6 months.

          -  Subject has &gt;2 x upper limit of normal (ULN) of any of the following at the Entry
             Visit (EV): alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline
             phosphatase (ALP), or &gt;ULN total bilirubin (≥1.5x ULN total bilirubin if known
             Gilbert's syndrome).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ep0085 111</name>
      <address>
        <city>Hamamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 110</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 121</name>
      <address>
        <city>Itami</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 102</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 123</name>
      <address>
        <city>Kodaira</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 115</name>
      <address>
        <city>Kokubunji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 112</name>
      <address>
        <city>Koshi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 128</name>
      <address>
        <city>Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 124</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 106</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 114</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 116</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 101</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 103</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 104</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 109</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 120</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0085 850</name>
      <address>
        <city>Ōsaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brivaracetam</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Partial seizures with or without secondary generalization</keyword>
  <keyword>Asian subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivaracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

